JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1988; 12:1599-1604
© 1988 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Factor, S.
Right arrow Articles by Malhotra, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Factor, S.
Right arrow Articles by Malhotra, A

Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy

SM Factor, SH Cho, J Scheuer, EH Sonnenblick, and A Malhotra

Department of Pathology, Albert Einstein College of Medicine, New York 10461.

The cardiomyopathic Syrian hamster develops genetically determined cardiac necrosis that invariably leads to premature death from congestive heart failure or arrhythmia. This hamster is a valuable model of human disease because it has many features in common with clinical dilated, congestive cardiomyopathy. Previous studies have shown that therapy for several weeks with the calcium channel blocking drug verapamil or the alpha-1 adrenoceptor blocking drug prazosin can prevent myocardial necrosis due to microvascular spasm. Other investigations have demonstrated the positive effects of verapamil in the early stages of disease. It is not clear, however, whether continued treatment can prevent the long-term expression of the cardiomyopathy or whether the disease is genetically predetermined. To address this question, hamsters were treated with oral verapamil for 7 to 8 months during the necrotizing, compensatory hypertrophy and early failure stages of disease. Analysis of myocardial pathologic and biochemical variables demonstrated that continuously treated animals were generally similar to unaffected control hamsters; discontinuous therapy led to partial protection. These findings demonstrate that virtually complete prevention of this hereditary disease is feasible; these results may have important implications for the treatment of human cardiomyopathy.


This article has been cited by other articles:


Home page
 Circ. Res.Home page
K. A. Lapidos, R. Kakkar, and E. M. McNally
The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma
Circ. Res., April 30, 2004; 94(8): 1023 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Engelhardt, L. Hein, V. Dyachenkow, E. G. Kranias, G. Isenberg, and M. J. Lohse
Altered Calcium Handling Is Critically Involved in the Cardiotoxic Effects of Chronic {beta}-Adrenergic Stimulation
Circulation, March 9, 2004; 109(9): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. T. Wheeler, C. E. Korcarz, K. A. Collins, K. A. Lapidos, A. A. Hack, M. R. Lyons, S. Zarnegar, J. U. Earley, R. M. Lang, and E. M. McNally
Secondary Coronary Artery Vasospasm Promotes Cardiomyopathy Progression
Am. J. Pathol., March 1, 2004; 164(3): 1063 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. E. Woodman, D. S. Park, A. W. Cohen, M. W.-C. Cheung, M. Chandra, J. Shirani, B. Tang, L. A. Jelicks, R. N. Kitsis, G. J. Christ, et al.
Caveolin-3 Knock-out Mice Develop a Progressive Cardiomyopathy and Show Hyperactivation of the p42/44 MAPK Cascade
J. Biol. Chem., October 4, 2002; 277(41): 38988 - 38997.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. A. Mathier, G. A. Rose, M. A. Fifer, M. I. Miyamoto, R. E. Dinsmore, H. H. Castano, G. W. Dec, I. F. Palacios, and M. J. Semigran
Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy
J. Am. Coll. Cardiol., July 1, 1998; 32(1): 216 - 224.
[Abstract] [Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1988 by the American College of Cardiology Foundation.